top of page

Pavaka and The Fischer Group Complete Second-Generation Dressing Design Optimization for Scalable Manufacturing

Writer: Brent Toto
Brent Toto
Aug 27
2 min read

Updated: 7 days ago

FAIRFIELD, Ohio — August 27, 2026 — Pavaka Wound Care and its manufacturing partner, The Fischer Group of Fairfield, Ohio, have completed the design-optimization phase of Pavaka's second-generation (Gen 2) electroceutical wound dressing. Gen 2 is engineered for scalable, high-speed production. Gen 2 has not been studied in patients; clinical results to date are from the Gen 1 dressing.


The project was supported by the Technology Validation and Start-up Fund (TVSF) award Pavaka received from the Ohio Department of Development in April 2025, and it is one of that award's core milestones. The teams researched raw materials and suppliers, evaluated power-supply options and high-speed manufacturing processes, and finalized a layered dressing architecture designed for line production rather than hand assembly.


The Fischer Group has built more than 600 Gen 1 dressings for clinical research. Pavaka received the first working Gen 2 prototype capable of high-speed line production in December 2025, and the teams have refined the design since. The phase closed out on August 27, 2026, with The Fischer Group's documentation of the work completed.


Gen 2 keeps the core principle of Pavaka's platform, a dressing that generates a low-level electric field at the wound surface, while condensing the design into a format built for efficient manufacturing. The dressing is built on technology exclusively licensed from The Ohio State University and remains investigational.


Manufacturing in Ohio has been part of Pavaka's plan from the start. Working with an established Ohio manufacturer lets the company iterate quickly, keep engineering and production teams in close contact, and build a supply chain that can grow with demand.


With design optimization complete, Pavaka is moving into the next stages of product development and regulatory preparation. The Fischer Group is building to ISO 13485, ISO compliant.


Pavaka thanks Al Fischer, Lori Brecht and The Fischer Group team, along with the Ohio Department of Development and Ohio Third Frontier, for their partnership.


The milestone also demonstrates the value of Ohio's Technology Validation and Start-up Fund. The program helps university-licensed startups bridge the gap between a working research prototype and a product ready for commercial manufacturing.


"Designing a medical device that can be made at speed, in Ohio, is just as important as the science behind it. The Fischer Group has been an outstanding partner in getting Gen 2 to this point." — Brent Toto, CEO and Co-Founder

Investigational device: Pavaka's electroceutical wound dressing has not been cleared or approved by the U.S. Food and Drug Administration and is not available for sale.


About Pavaka Wound Care: Pavaka Wound Care is a Columbus, Ohio–based medical device company developing an electroceutical advanced wound dressing for chronic and acute wounds, including wounds complicated by multidrug-resistant bacteria and biofilms. Built on technology exclusively licensed from The Ohio State University, the investigational dressing generates a low-level electric field at the wound surface. Pavaka was co-founded by CEO Brent Toto and CTO Frank Fischer. Learn more at www.pavakawoundcare.com.


Sources and further reading

Comments


bottom of page